Daniel Christ
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Christ has a total of 684 co-authors. Here are the top co-authors by number of shared publications:
Peter Schofield
25 shared publications- Romain Rouet
Garvan Institute of Medical Research
24 shared publications - David Brent Langley
Immune Biotherapies Program, Garvan Institute of Medical Research, Australia
16 shared publications - Christopher C. Goodnow
Garvan Institute of Medical Research, Sydney, Australia
12 shared publications Robert Brink
The Garvan Institute of Medical Research, Sydney, Australia
11 shared publicationsJennifer Jackson
Garvan Institute of Medical Research , Darlinghurst, Sydney, NSW 2010 , Australia
10 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Nature Communications
Energy-guided combinatorial co-optimization of antibody affinity and stability
- 5 November 2026
- Published by Springer Nature in Nature Communications
Open AccessEnergy-guided combinatorial co-optimization of antibody affinity and stability
- 27 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (961)
Disruption of the N-terminal domain in a STAT3 hyper-IgE syndrome variant causes disease by sequestering STAT3 in the cytoplasm
Autosomal-dominant hyper-IgE syndrome (HIES) is characterized by chronic mucocutaneous candidiasis, recurrent sinopulmonary complications, noninflammatory atopic dermatitis, high amounts of serum IgE, and nonimmunological manifestations affecting the musculoskeletal and vascular systems. Most cases are caused by heterozygous loss-of-function, dominant-negative (LOF/DN) variants that affect the DNA binding, SH2, or transactivation domains of STAT3. Here, we report a patient with a unique STAT3 allele affecting the STAT3 N-terminal domain (R31Q), who presented with disseminated invasive aspergillosis affecting the brain and lung, bronchiectasis, and high serum IgE but lacked nonimmune disease manifestations. Biochemical analyses in cell lines demonstrated that R31Q reduced the abundance and transcriptional activity of STAT3 and caused it to exhibit negative dominance on wild-type (WT) STAT3. This was due to preferential STAT3 R31Q dimerization with STAT3 WT , sequestration of STAT3 WT :STAT3 R31Q dimers in the cytosol, and a reduction in STAT3 nuclear translocation and transcriptional activity. Lymphocytes from the patient exhibited some typical defects observed in canonical STAT3 LOF/DN HIES, such as reduced memory B cells, MAIT cells, and T H 17 cytokines. However, naïve B cells from this patient had only a partial impairment in immunoglobulin secretion induced by interleukin-21 (IL-21) in vitro, and the patient had normal numbers of T H 2 cells and circulating T FH cells. Our findings reveal that the N-terminal domain regulates STAT3 dimer formation and function and provide a previously unknown biochemical mechanism of disease pathogenesis in STAT3 LOF/DN HIES.
- 27 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (961)
Disruption of the N-terminal domain in a STAT3 hyper-IgE syndrome variant causes disease by sequestering STAT3 in the cytoplasm
Autosomal-dominant hyper-IgE syndrome (HIES) is characterized by chronic mucocutaneous candidiasis, recurrent sinopulmonary complications, noninflammatory atopic dermatitis, high amounts of serum IgE, and nonimmunological manifestations affecting the musculoskeletal and vascular systems. Most cases are caused by heterozygous loss-of-function, dominant-negative (LOF/DN) variants that affect the DNA binding, SH2, or transactivation domains of STAT3. Here, we report a patient with a unique STAT3 allele affecting the STAT3 N-terminal domain (R31Q), who presented with disseminated invasive aspergillosis affecting the brain and lung, bronchiectasis, and high serum IgE but lacked nonimmune disease manifestations. Biochemical analyses in cell lines demonstrated that R31Q reduced the abundance and transcriptional activity of STAT3 and caused it to exhibit negative dominance on wild-type (WT) STAT3. This was due to preferential STAT3 R31Q dimerization with STAT3 WT , sequestration of STAT3 WT :STAT3 R31Q dimers in the cytosol, and a reduction in STAT3 nuclear translocation and transcriptional activity. Lymphocytes from the patient exhibited some typical defects observed in canonical STAT3 LOF/DN HIES, such as reduced memory B cells, MAIT cells, and T H 17 cytokines. However, naïve B cells from this patient had only a partial impairment in immunoglobulin secretion induced by interleukin-21 (IL-21) in vitro, and the patient had normal numbers of T H 2 cells and circulating T FH cells. Our findings reveal that the N-terminal domain regulates STAT3 dimer formation and function and provide a previously unknown biochemical mechanism of disease pathogenesis in STAT3 LOF/DN HIES.
- Open Access
- 9 January 2026
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 39
Protein engineering: status report
With this status report, we aim to provide a timely snapshot of the protein engineering field as a broad and rapidly advancing discipline that integrates computational, molecular biology, structure-guided, evolutionary, and synthetic approaches to create new and improved proteins with tailored structures and useful functions. The report is organized into eight thematic areas spanning core methodologies and major application domains, including enzymes, therapeutics, detection, synthetic biology, and materials. Contributions from experts across these areas highlight both the historical foundations and recent advances in their respective fields, with particular emphasis on the growing influence of machine learning and artificial intelligence-based methods. Emerging from this broad overview is a central message: protein engineering appears to be entering a golden age, defined by a rapidly accelerating pace of progress, even as significant challenges in design, screening, and real-world application remain. Looking ahead, the continued integration of computational and experimental strategies is poised to further accelerate the impact of protein engineering across an expanding range of economically and societally important sectors, from therapeutics and molecular imaging to diagnostics, plastic recycling, and industrial chemistry.
- 9 January 2026
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 39
Open AccessProtein engineering: status report
With this status report, we aim to provide a timely snapshot of the protein engineering field as a broad and rapidly advancing discipline that integrates computational, molecular biology, structure-guided, evolutionary, and synthetic approaches to create new and improved proteins with tailored structures and useful functions. The report is organized into eight thematic areas spanning core methodologies and major application domains, including enzymes, therapeutics, detection, synthetic biology, and materials. Contributions from experts across these areas highlight both the historical foundations and recent advances in their respective fields, with particular emphasis on the growing influence of machine learning and artificial intelligence-based methods. Emerging from this broad overview is a central message: protein engineering appears to be entering a golden age, defined by a rapidly accelerating pace of progress, even as significant challenges in design, screening, and real-world application remain. Looking ahead, the continued integration of computational and experimental strategies is poised to further accelerate the impact of protein engineering across an expanding range of economically and societally important sectors, from therapeutics and molecular imaging to diagnostics, plastic recycling, and industrial chemistry.
- 15 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (51) , 47869-47870
Correction to “DNA G-Quadruplex and i-Motif Structure Formation Is Interdependent in Human Cells”
- 15 December 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (51) , 47869-47870
Correction to “DNA G-Quadruplex and i-Motif Structure Formation Is Interdependent in Human Cells”
- Open Access
- 14 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (11) , eadq4416
Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlling energy homeostasis, has also been shown to promote tumorigenesis in a range of cancer types, but its role in PC has yet to be explored. We show that expression of NPY and NPY1R are up-regulated in mouse PC models and human patients with PC. Moreover, using the genetically engineered, autochthonous KP R172H C mouse model of PC, we demonstrate that pancreas-specific and whole-body knockout of Npy1r significantly decreases metastasis to the liver. We identify that treatment with the NPY1R antagonist BIBO3304 significantly reduces KP R172H C migratory capacity on cell-derived matrices. Pharmacological NPY1R inhibition in an intrasplenic model of PC metastasis recapitulated the results of our genetic studies, with BIBO3304 significantly decreasing liver metastasis. Together, our results reveal that NPY/NPY1R signaling is a previously unidentified antimetastatic target in PC.
- 14 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (11) , eadq4416
Open AccessTargeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlling energy homeostasis, has also been shown to promote tumorigenesis in a range of cancer types, but its role in PC has yet to be explored. We show that expression of NPY and NPY1R are up-regulated in mouse PC models and human patients with PC. Moreover, using the genetically engineered, autochthonous KP R172H C mouse model of PC, we demonstrate that pancreas-specific and whole-body knockout of Npy1r significantly decreases metastasis to the liver. We identify that treatment with the NPY1R antagonist BIBO3304 significantly reduces KP R172H C migratory capacity on cell-derived matrices. Pharmacological NPY1R inhibition in an intrasplenic model of PC metastasis recapitulated the results of our genetic studies, with BIBO3304 significantly decreasing liver metastasis. Together, our results reveal that NPY/NPY1R signaling is a previously unidentified antimetastatic target in PC.
- Open Access
- 7 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Structure and dynamics of GAD65 in complex with an autoimmune polyendocrine syndrome type 2-associated autoantibody
The enzyme glutamate decarboxylase (GAD) produces the neurotransmitter GABA, using pyridoxal-5’-phosphate (PLP). GAD exists as two isoforms, GAD65 and GAD67. Only GAD65 acts as a major autoantigen, frequently implicated in type 1 diabetes and other autoimmune diseases. Here we characterize the structure and dynamics of GAD65 and its interaction with the autoimmune polyendocrine syndrome type 2-associated autoantibody b96.11. Using hydrogen-deuterium exchange mass spectrometry (HDX), X-ray crystallography, cryo-electron microscopy, and computational approaches, we examine the conformational dynamics of apo- and holoGAD65 and the GAD65-autoantibody complex. HDX reveals local dynamics accompanying autoinactivation, with the catalytic loop promoting collective motions at the CTD-PLP domain interface. In the GAD65-b96.11 complex, heavy chain CDRs dominate the interaction, with a long CDRH3 bridging the GAD65 dimer via electrostatic interactions with the 260PEVKEK265motif. This bridging links structural elements controlling GAD65’s conformational flexibility to its autoantigenicity. Thus, intrinsic dynamics, rather than sequence differences within epitopes, appear to be responsible for the contrasting autoantigenicities of GAD65 and GAD67. Our findings elucidate the structural and dynamic factors that govern the varying autoantibody reactivities of GAD65 and GAD67, offering a revised rationale for the autoimmune response to GAD65.
- 7 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessStructure and dynamics of GAD65 in complex with an autoimmune polyendocrine syndrome type 2-associated autoantibody
The enzyme glutamate decarboxylase (GAD) produces the neurotransmitter GABA, using pyridoxal-5’-phosphate (PLP). GAD exists as two isoforms, GAD65 and GAD67. Only GAD65 acts as a major autoantigen, frequently implicated in type 1 diabetes and other autoimmune diseases. Here we characterize the structure and dynamics of GAD65 and its interaction with the autoimmune polyendocrine syndrome type 2-associated autoantibody b96.11. Using hydrogen-deuterium exchange mass spectrometry (HDX), X-ray crystallography, cryo-electron microscopy, and computational approaches, we examine the conformational dynamics of apo- and holoGAD65 and the GAD65-autoantibody complex. HDX reveals local dynamics accompanying autoinactivation, with the catalytic loop promoting collective motions at the CTD-PLP domain interface. In the GAD65-b96.11 complex, heavy chain CDRs dominate the interaction, with a long CDRH3 bridging the GAD65 dimer via electrostatic interactions with the 260PEVKEK265motif. This bridging links structural elements controlling GAD65’s conformational flexibility to its autoantigenicity. Thus, intrinsic dynamics, rather than sequence differences within epitopes, appear to be responsible for the contrasting autoantigenicities of GAD65 and GAD67. Our findings elucidate the structural and dynamic factors that govern the varying autoantibody reactivities of GAD65 and GAD67, offering a revised rationale for the autoimmune response to GAD65.
- Open Access
- 11 January 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (2)
The iMab antibody selectively binds to intramolecular and intermolecular i-motif structures
I-Motifs (iMs) are quadruplex nucleic acid conformations that form in cytosine-rich regions. Because of their acidic pH dependence, iMs were thought to form only in vitro. The recent development of an iM-selective antibody, iMab, has allowed iM detection in cells, which revealed their presence at gene promoters and their cell cycle dependence. However, recent evidence emerged which appeared to suggest that iMab recognizes C-rich sequences regardless of their iM conformation. To further investigate the selectivity of iMab, we examined the binding of iMab to C-rich sequences, using a combination of pull-down and western blot assays. Here, we observe that the composition of buffers used during binding and washing steps strongly influences the selectivity of antibody binding. In addition, we demonstrate by nuclear magnetic resonance that several of the previously reported C-rich sequences, which were not expected to form iMs, actually form intermolecular iMs which are selectively recognized by iMab. Our results highlight the specificity of the iMab antibody, emphasize the importance of avoiding in vitro artifacts by optimizing DNA concentrations, blocking and washing conditions, and confirm that iMab is selective not only for intramolecular iMs but also for intermolecular iMs, while not affecting the iM conformation.
- 11 January 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (2)
Open AccessThe iMab antibody selectively binds to intramolecular and intermolecular i-motif structures
I-Motifs (iMs) are quadruplex nucleic acid conformations that form in cytosine-rich regions. Because of their acidic pH dependence, iMs were thought to form only in vitro. The recent development of an iM-selective antibody, iMab, has allowed iM detection in cells, which revealed their presence at gene promoters and their cell cycle dependence. However, recent evidence emerged which appeared to suggest that iMab recognizes C-rich sequences regardless of their iM conformation. To further investigate the selectivity of iMab, we examined the binding of iMab to C-rich sequences, using a combination of pull-down and western blot assays. Here, we observe that the composition of buffers used during binding and washing steps strongly influences the selectivity of antibody binding. In addition, we demonstrate by nuclear magnetic resonance that several of the previously reported C-rich sequences, which were not expected to form iMs, actually form intermolecular iMs which are selectively recognized by iMab. Our results highlight the specificity of the iMab antibody, emphasize the importance of avoiding in vitro artifacts by optimizing DNA concentrations, blocking and washing conditions, and confirm that iMab is selective not only for intramolecular iMs but also for intermolecular iMs, while not affecting the iM conformation.
- Open Access
- 2 January 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (1)
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies
The emergence of SARS-CoV-2 variants of concern (VOCs) has greatly diminished the neutralizing activity of previously FDA-approved monoclonal antibodies (mAbs), including that of antibody cocktails and of first-generation broadly neutralizing antibodies such as S309 (Sotrovimab). In contrast, antibodies targeting cryptic conformational epitopes of the receptor binding domain (RBD) have demonstrated broad activity against emerging variants, but exert only moderate neutralizing activity, which has so far hindered clinical development. Here, we utilize in vitro display technology to identify and affinity-mature antibodies targeting the cryptic class 6 epitope, accessible only in the “up” conformation of the SARS-CoV-2 spike trimer. Increasing antibody affinity into the low picomolar range endowed potent neutralization of VOCs and protection of hACE2 mice from viral challenge. Cryoelectron microscopy and crystal structures of two affinity-matured antibodies (4C12-B12 and 4G1-C2) in complex with RBD highlighted binding modes and epitopes distal from mutational hotspots commonly overserved in VOCs, providing direct structural insights into the observed mutational resistance. Moreover, we further demonstrate that antibodies targeting the class 6 epitope, rather than being an artifact of in vitro selection, are common in the IgG1 + memory B cell repertoire of convalescent patients and can be induced in human antibody V-gene transgenic mice through immunization. Our results highlight the importance of very high (picomolar) affinity in the development of neutralizing antibodies and vaccines and suggest an affinity threshold in the provision of broad and long-lasting immunity against SARS-CoV-2.
- 2 January 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (1)
Open AccessAffinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies
The emergence of SARS-CoV-2 variants of concern (VOCs) has greatly diminished the neutralizing activity of previously FDA-approved monoclonal antibodies (mAbs), including that of antibody cocktails and of first-generation broadly neutralizing antibodies such as S309 (Sotrovimab). In contrast, antibodies targeting cryptic conformational epitopes of the receptor binding domain (RBD) have demonstrated broad activity against emerging variants, but exert only moderate neutralizing activity, which has so far hindered clinical development. Here, we utilize in vitro display technology to identify and affinity-mature antibodies targeting the cryptic class 6 epitope, accessible only in the “up” conformation of the SARS-CoV-2 spike trimer. Increasing antibody affinity into the low picomolar range endowed potent neutralization of VOCs and protection of hACE2 mice from viral challenge. Cryoelectron microscopy and crystal structures of two affinity-matured antibodies (4C12-B12 and 4G1-C2) in complex with RBD highlighted binding modes and epitopes distal from mutational hotspots commonly overserved in VOCs, providing direct structural insights into the observed mutational resistance. Moreover, we further demonstrate that antibodies targeting the class 6 epitope, rather than being an artifact of in vitro selection, are common in the IgG1 + memory B cell repertoire of convalescent patients and can be induced in human antibody V-gene transgenic mice through immunization. Our results highlight the importance of very high (picomolar) affinity in the development of neutralizing antibodies and vaccines and suggest an affinity threshold in the provision of broad and long-lasting immunity against SARS-CoV-2.
- Open Access
- 29 August 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (20) , 4786-4804
Human genomic DNA is widely interspersed with i-motif structures
DNA i-motif structures are formed in the nuclei of human cells and are believed to provide critical genomic regulation. While the existence, abundance, and distribution of i-motif structures in human cells has been demonstrated and studied by immunofluorescent staining, and more recently NMR and CUT&Tag, the abundance and distribution of such structures in human genomic DNA have remained unclear. Here we utilise high-affinity i-motif immunoprecipitation followed by sequencing to map i-motifs in the purified genomic DNA of human MCF7, U2OS and HEK293T cells. Validated by biolayer interferometry and circular dichroism spectroscopy, our approach aimed to identify DNA sequences capable of i-motif formation on a genome-wide scale, revealing that such sequences are widely distributed throughout the human genome and are common in genes upregulated in G0/G1 cell cycle phases. Our findings provide experimental evidence for the widespread formation of i-motif structures in human genomic DNA and a foundational resource for future studies of their genomic, structural, and molecular roles.
- 29 August 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (20) , 4786-4804
Open AccessHuman genomic DNA is widely interspersed with i-motif structures
DNA i-motif structures are formed in the nuclei of human cells and are believed to provide critical genomic regulation. While the existence, abundance, and distribution of i-motif structures in human cells has been demonstrated and studied by immunofluorescent staining, and more recently NMR and CUT&Tag, the abundance and distribution of such structures in human genomic DNA have remained unclear. Here we utilise high-affinity i-motif immunoprecipitation followed by sequencing to map i-motifs in the purified genomic DNA of human MCF7, U2OS and HEK293T cells. Validated by biolayer interferometry and circular dichroism spectroscopy, our approach aimed to identify DNA sequences capable of i-motif formation on a genome-wide scale, revealing that such sequences are widely distributed throughout the human genome and are common in genes upregulated in G0/G1 cell cycle phases. Our findings provide experimental evidence for the widespread formation of i-motif structures in human genomic DNA and a foundational resource for future studies of their genomic, structural, and molecular roles.
- Open Access
The iMab antibody selectively binds to intramolecular and intermolecular i-motif structures
I-Motifs are quadruplex nucleic acid conformations that form in cytosine-rich regions. Because of their acidic pH dependence, iMs were thought to form only in vitro . The recent development of an iM-selective antibody, iMab, has allowed iM detection in cells, which revealed their presence at gene promoters and their cell cycle dependence. However, recently evidence emerged which seemed to suggest that iMab recognizes C-rich sequences regardless of their iM conformation. To further investigate the selectivity of iMab, we examined the binding of iMab to C-rich sequences, using a combination of pull-down and Western blot assays. Here we observe that the composition of buffers used during binding and washing steps strongly influences the selectivity of antibody binding. In addition, we demonstrate by NMR that several of the previously reported C-rich sequences, which were not expected to form iMs, actually form intermolecular iMs which are selectively recognized by iMab. Our results highlight the specificity of the iMab antibody, emphasize the importance of optimizing DNA concentrations, blocking and washing conditions, and confirm iMab selectivity not only for intramolecular iMs, but also for intermolecular iMs.
Open AccessThe iMab antibody selectively binds to intramolecular and intermolecular i-motif structures
I-Motifs are quadruplex nucleic acid conformations that form in cytosine-rich regions. Because of their acidic pH dependence, iMs were thought to form only in vitro . The recent development of an iM-selective antibody, iMab, has allowed iM detection in cells, which revealed their presence at gene promoters and their cell cycle dependence. However, recently evidence emerged which seemed to suggest that iMab recognizes C-rich sequences regardless of their iM conformation. To further investigate the selectivity of iMab, we examined the binding of iMab to C-rich sequences, using a combination of pull-down and Western blot assays. Here we observe that the composition of buffers used during binding and washing steps strongly influences the selectivity of antibody binding. In addition, we demonstrate by NMR that several of the previously reported C-rich sequences, which were not expected to form iMs, actually form intermolecular iMs which are selectively recognized by iMab. Our results highlight the specificity of the iMab antibody, emphasize the importance of optimizing DNA concentrations, blocking and washing conditions, and confirm iMab selectivity not only for intramolecular iMs, but also for intermolecular iMs.